Evidence map›Paper›PMID 37953502›Full record

ReviewCNS neuroscience & therapeutics2024

The regulatory role and clinical application prospects of circRNA in the occurrence and development of CNS tumors.

Bo Zhang, Hao Zhang, Zeyu Wang, Hui Cao, Nan Zhang, Ziyu Dai, Xisong Liang, Yun Peng, Jie Wen, Xun Zhang and 6 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in CNS neuroscience & therapeutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 2 countries.

Bo ZhangDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China.
Hao ZhangDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China.
Zeyu WangDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China.
Hui CaoDepartment of Psychiatry, The School of Clinical Medicine, Hunan University of Chinese Medicine, Changsha, China.
Nan ZhangCollege of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, China.
Ziyu DaiDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China.
Xisong LiangDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China.
Yun PengTeaching and Research Section of Clinical Nursing, Xiangya Hospital of Central South University, Changsha, China.
Jie WenDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China.
Xun ZhangDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China.
Liyang ZhangDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China.ORCID 0000-0002-4054-1667
Peng LuoDepartment of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Jian ZhangDepartment of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Zaoqu LiuDepartment of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Quan ChengDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China.ORCID 0000-0003-2401-5349
Renjun PengDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China.
Central South University · CNZhujiang Hospital · CNFirst Affiliated Hospital of Zhengzhou University · CNHuazhong University of Science and Technology · CNHunan University of Traditional Chinese Medicine · CN

Funding

Hunan Provincial Health Committee Foundation of China 202204044869National Natural Science Foundation of China 81703622National Natural Science Foundation of China 81901268National Natural Science Foundation of China 82073893Natural Science Foundation of Hunan Province 2022JJ20095
6 · The paper itself

Abstract

backgroundCentral nervous system (CNS) tumors originate from the spinal cord or brain. The study showed that even with aggressive treatment, malignant CNS tumors have high mortality rates. However, CNS tumor risk factors and molecular mechanisms have not been verified. Due to the reasons mentioned above, diagnosis and treatment of CNS tumors in clinical practice are currently fraught with difficulties. Circular RNAs (circRNAs), single-stranded ncRNAs with covalently closed continuous structures, are essential to CNS tumor development. Growing evidence has proved the numeral critical biological functions of circRNAs for disease progression: sponging to miRNAs, regulating gene transcription and splicing, interacting with proteins, encoding proteins/peptides, and expressing in exosomes.

aimsThis review aims to summarize current progress regarding the molecular mechanism of circRNA in CNS tumors and to explore the possibilities of clinical application based on circRNA in CNS tumors.

methodsWe have summarized studies of circRNA in CNS tumors in Pubmed.

resultsThis review summarized their connection with CNS tumors and their functions, biogenesis, and biological properties. Furthermore, we introduced current advances in clinical RNA-related technologies. Then we discussed the diagnostic and therapeutic potential (especially for immunotherapy, chemotherapy, and radiotherapy) of circRNA in CNS tumors in the context of the recent advanced research and application of RNA in clinics.

conclusionsCircRNA are increasingly proven to participate in decveloping CNS tumors. An in-depth study of the causal mechanisms of circRNAs in CNS tomor progression will ultimately advance their implementation in the clinic and developing new strategies for preventing and treating CNS tumors.

Indexed as

MicroRNAsNeoplasmsHumansRNA, CircularMicroRNAsRNA, CircularchemotherapycircRNACNS tumorsimmunotherapyradiotherapy

Identifiers

PMID37953502
PMCPMC11017455
OpenAlexW4388637215

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.